Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Strontium-89 × Clear all
NCT00080782 2018-10-31

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

M.D. Anderson Cancer Center

Phase 2 Terminated
14 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00081159 2016-11-10

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

M.D. Anderson Cancer Center

Phase 2 Completed
80 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00156884 2012-01-19

A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer

AHS Cancer Control Alberta

Phase 2 Completed
58 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡